OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center near Munich, is a privately held medical device company which is specialized in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotopes. Since its foundation in 2010, OncoBeta® GmbH has concentrated its efforts on the development and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy) targeting non-melanoma skin cancers. Since then OncoBeta® has successfully perfected the customised application and device management system in conformity with all health, safety, and environmental protection regulatory standards achieving the European CE certification in Germany, an important milestone for a specialized medical device company.
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to also make this personalised, painless and non-invasive therapy accessible to patients in countries outside the European Union. The Rhenium-SCT® significantly improves the quality of life outcomes of non-melanoma skin cancer patients attaining sensational aesthetic results as well as reducing most all side-effects and improves health economics which must be accessible to everyone.
OncoBeta® GmbH is very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Future oriented, we seek, develop and deliver therapies which provide painless, customized, single-session applications that achieve exceptional cosmetic results.
Our highly advanced and effective Rhenium-SCT® (Skin Cancer Therapy) was created in collaboration with the wants and needs expressed by physicians and their patients as well as a strong emphasis on economic and ethical criteria.
Our current mission is to continuously improve the quality of life of patients suffering from non-melanoma skin cancer, the world’s most common tumours of the skin.
Our primary goal is to offer an effective, customized and non-invasive treatment, independent of tumour size, severity and localization. Providing a fast, painless, single treatment, with no side effects and aesthetic results.
We do this by further developing our innovative therapeutic applications with the use of modern radioisotopes and state-of-the-art application equipment achieving genuine added value with an extreme emphasis on ethical and economic criteria.
We are working relentlessly to increase our current therapeutic portfolio, while constantly striving to develop additional non-invasive therapies in the areas of dermatology and oncology for patients in need.
A strong desire to alleviate suffering and be able to walk in the shoes of the people we server and work with.
Developing effective and personalized solutions for physicians and their patients.
Demonstrating excellence in everything we do.
Showing regard, consideration and thankful recognition to each other.
Cooperative and coordinated efforts in the interests of our common cause.
Focus on the job at hand to improve the quality of treatment and/or service.
Adherence to moral and ethical principles, honour commitments and never compromise ethics in all our dealings.
Being open and truthful in all things we do.